130
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Water-Soluble C60 Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice

, , , , , , ORCID Icon, & show all
Pages 2269-2276 | Published online: 31 Mar 2020

References

  • Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi:10.1164/rccm.2009-040GL21471066
  • Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–151. doi:10.7326/0003-4819-134-2-200101160-0001511177318
  • Wadsworth RM. Oxidative stress and the endothelium. Exp Physiol. 2008;93(1):155–157. doi:10.1113/expphysiol.2007.03868718165435
  • Teixeira KC, Soares FS, Rocha LG, et al. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulm Pharmacol Ther. 2008;21(2):309–316. doi:10.1016/j.pupt.2007.07.00617904883
  • Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987;79(6):1665–1673. doi:10.1172/JCI1130053034979
  • Daniil ZD, Papageorgiou E, Koutsokera A, et al. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2008;21(1):26–31. doi:10.1016/j.pupt.2006.10.00517161968
  • Krusic PJ, Wasserman E, Keizer PN, et al. Radical reactions of c60. Science. 1991;254(5035):1183–1185. doi:10.1126/science.254.5035.118317776407
  • Gharbi N, Pressac M, Hadchouel M, et al. [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005;5(12):2578–2585. doi:10.1021/nl051866b16351219
  • Johnston HJ, Hutchison GR, Christensen FM, et al. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci. 2010;114(2):162–182. doi:10.1093/toxsci/kfp26519901017
  • Qiao R, Roberts AP, Mount AS, et al. Translocation of C60 and its derivatives across a lipid bilayer. Nano Lett. 2007;7(3):614–619. doi:10.1021/nl062515f17316055
  • Prylutska S, Bilyy R, Overchuk M, et al. Water-soluble pristine fullerenes C60 increase the specific conductivity and capacity of lipid model membrane and form the channels in cellular plasma membrane. J Biomed Nanotechnol. 2012;8(3):522–527. doi:10.1166/jbn.2012.140422764423
  • Shi J, Wang L, Gao J, et al. A fullerene-based multi-functional nanoplatform for cancer theranostic applications. Biomaterials. 2014;35(22):5771–5784. doi:10.1016/j.biomaterials.2014.03.07124746227
  • Panchuk RR, Prylutska SV, Chumakl VV, et al. Application of C60 Fullerene-doxorubicin complex for tumor cell treatment in vitro and in vivo. J Biomed Nanotechnol. 2015;11(7):1139–1152. doi:10.1166/jbn.2015.205826307837
  • Li XX, Jiang DY, Huang XX, et al. Toll-like receptor 4 promotes fibrosis in bleomycin-induced lung injury in mice. Genet Mol Res. 2015;14(4):17391–17398. doi:10.4238/2015.December.21.826782380
  • Jiang D, Liang J, Hodge J, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest. 2004;114(2):291–299. doi:10.1172/JCI1686115254596
  • Jiang DY, Huang XX, Jing G, et al. Pulmonary fibrosis in a mouse model of sarcoid granulomatosis induced by booster challenge with Propionibacterium acnes. Oncotarget. 2016;7(23):33703–33714. doi:10.18632/oncotarget.939727203210
  • Hübner RH, Gitter W, El MNE, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44(4):507–11, 514–7. doi:10.2144/000112729
  • Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(3):254–263. doi:10.1164/rccm.200810-1615OC19850947
  • Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525–34. doi:10.1152/ajplung.00163.200717631612
  • Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med. 2011;17(5):355–361. doi:10.1097/MCP.0b013e328349ac2b21832918
  • Gao F, Koenitzer JR, Tobolewski JM, et al. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem. 2008;283(10):6058–6066. doi:10.1074/jbc.M70927320018165226
  • Liu G, Beri R, Mueller A, Kamp DW. Molecular mechanisms of asbestos-induced lung epithelial cell apoptosis. Chem Biol Interact. 2010;188(2):309–318. doi:10.1016/j.cbi.2010.03.04720380827
  • Fu YQ, Fang F, Lu ZY, et al. N-acetylcysteine protects alveolar epithelial cells from hydrogen peroxide-induced apoptosis through scavenging reactive oxygen species and suppressing c-Jun N-terminal kinase. Exp Lung Res. 2010;36(6):352–361. doi:10.3109/0190214100367858220653470
  • Jorgensen E, Stinson A, Shan L, et al. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer. 2008;8(1):229. doi:10.1186/1471-2407-8-22918694499
  • Rees MD, Kennett EC, Whitelock JM, et al. Oxidative damage to extracellular matrix and its role in human pathologies. Free Radic Biol Med. 2008;44(12):1973–2001. doi:10.1016/j.freeradbiomed.2008.03.01618423414
  • Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976–985. doi:10.1183/09031936.0015210617301095
  • Sime PJ, O’Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99(3):308–319. doi:10.1006/clim.2001.500811358425
  • Cuzzocrea S, Genovese T, Failla M, et al. Protective effect of orally administered carnosine on bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1095–104. doi:10.1152/ajplung.00283.200617220373
  • Kang HR, Lee CG, Homer RJ, et al. Semaphorin 7A plays a critical role in TGF-β1–induced pulmonary fibrosis. J Exp Med. 2007;204(5):1083–1093. doi:10.1084/jem.2006127317485510
  • Failla M, Genovese T, Mazzon E, et al. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res. 2006;7(1):137. doi:10.1186/1465-9921-7-13717118201
  • Takeda Y, Tsujino K, Kijima T, et al. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence. 2014;8:361–370. doi:10.2147/PPA24711695
  • Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(5):740–747. doi:10.1111/resp.1229724836849
  • Mazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2015;9(3):121–129. doi:10.1177/175346581557936525862013
  • Baati T, Bourasset F, Gharbi N, et al. The prolongation of the lifespan of rats by repeated oral administration of [60]fullerene. Biomaterials. 2012;33(19):4936–4946. doi:10.1016/j.biomaterials.2012.03.03622498298